Payment overview · 2025
General Payments
$1,643.30
64 reported records · 16 companies
Healthcare provider profile · identity verified
Eldere Germain, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ORLANDO, FL · NPI 1467019109
Verified facts
What the public records show
CMS Open Payments records show Eldere Germain, MD received $1,643.30 in general payments during 2025 across 64 reported records.
GlaxoSmithKline, LLC. accounted for 20.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Paxlovid, Trelegy Ellipta, Wegovy.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 130 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $331.87 | 20.2% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $204.84 | 12.5% | 7 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $171.03 | 10.4% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $161.76 | 9.8% | 19 | 2025 |
| Avadel CNS Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $155.90 | 9.5% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $131.58 | 8.0% | 5 | 2025 |
| C2N Diagnostics, LLC | Unresolved — no canonical attribution shown | $130.66 | 8.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $89.21 | 5.4% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $63.76 | 3.9% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $47.95 | 2.9% | 3 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $47.64 | 2.9% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $38.56 | 2.4% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $23.54 | 1.4% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $18.21 | 1.1% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $16.23 | 1.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $10.56 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,643.30 | 64 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $190.91 | 6 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $171.03 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $161.76 | 19 | 2025 |
Source payment records
|
|||||
| LUMRYZ Normalized: lumryz |
Drug | Avadel CNS Pharmaceuticals, LLC | $155.90 | 2 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $147.33 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $141.78 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $137.00 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $134.00 | 5 | 2025 |
Source payment records
|
|||||
| PRECIVITYAD2 Normalized: precivityad2 |
Device | C2N Diagnostics, LLC | $130.66 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $89.21 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $89.21 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $69.87 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $50.01 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $50.01 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $47.64 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $38.56 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $28.81 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $28.81 | 2 | 2025 |
Source payment records
|
|||||
| OPSYNVI Normalized: opsynvi |
Drug | Actelion Pharmaceuticals US, Inc. | $23.70 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $23.54 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $18.21 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $16.23 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $13.93 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $13.75 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $10.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 131 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 130 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 75 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 107 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 23 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 51 | exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
130 | 36 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
75 | 27 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
51 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
75 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
107 | 30 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
131 | 36 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
23 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 575 | 216 |
| Levothyroxine Sodium | Levothyroxine Sodium | 554 | 184 |
| Amlodipine Besylate | Amlodipine Besylate | 488 | 187 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 454 | 171 |
| Lisinopril | Lisinopril | 410 | 161 |
| Metformin Hcl | Metformin Hcl | 371 | 132 |
| Omeprazole | Omeprazole | 339 | 129 |
| Losartan Potassium | Losartan Potassium | 338 | 137 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 317 | 125 |
| Gabapentin | Gabapentin | 301 | 122 |
| Alprazolam | Alprazolam | 289 | 73 |
| Furosemide | Furosemide | 242 | 110 |
| Pantoprazole Sodium | Pantoprazole Sodium | 229 | 90 |
| Glimepiride | Glimepiride | 224 | 91 |
| Metoprolol Tartrate | Metoprolol Tartrate | 217 | 85 |
| Prednisone | Prednisone | 217 | 152 |
| Zolpidem Tartrate | Zolpidem Tartrate | 213 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 209 | 80 |
| Azithromycin | Azithromycin | 206 | 164 |
| Trazodone Hcl | Trazodone Hcl | 197 | 61 |
| Meloxicam | Meloxicam | 182 | 68 |
| Metoprolol Succinate | Metoprolol Succinate | 171 | 64 |
| Escitalopram Oxalate | Escitalopram Oxalate | 160 | 61 |
| Simvastatin | Simvastatin | 153 | 61 |
| Alendronate Sodium | Alendronate Sodium | 149 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 139 | 55 |
| Amoxicillin | Amoxicillin | 136 | 114 |
| Eliquis | Apixaban | 131 | 36 |
| Farxiga | Dapagliflozin Propanediol | 130 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 128 | 52 |
| Tramadol Hcl | Tramadol Hcl | 128 | 42 |
| Ibuprofen | Ibuprofen | 125 | 72 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 122 | 100 |
| Famotidine | Famotidine | 118 | 50 |
| Montelukast Sodium | Montelukast Sodium | 118 | 51 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 108 | 34 |
| Glipizide | Glipizide | 107 | 38 |
| Ozempic | Semaglutide | 107 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 103 | 48 |
| Pravastatin Sodium | Pravastatin Sodium | 103 | 40 |
| Allopurinol | Allopurinol | 102 | 38 |
| Carvedilol | Carvedilol | 100 | 38 |
| Sertraline Hcl | Sertraline Hcl | 97 | 30 |
| Clonidine Hcl | Clonidine Hcl | 93 | 42 |
| Baclofen | Baclofen | 90 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 90 | 30 |
| Temazepam | Temazepam | 89 | 15 |
| Ketoconazole | Ketoconazole | 88 | 33 |
| Ezetimibe | Ezetimibe | 80 | 32 |
| Celecoxib | Celecoxib | 77 | 30 |
| Mirtazapine | Mirtazapine | 77 | 25 |
| Jardiance | Empagliflozin | 75 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 74 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 74 | 20 |
| Clonazepam | Clonazepam | 71 | 20 |
| Oxybutynin Chloride | Oxybutynin Chloride | 70 | 26 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 68 | 48 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 66 | 19 |
| Ofloxacin | Ofloxacin | 65 | 52 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 64 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 64 | 24 |
| Ropinirole Hcl | Ropinirole Hcl | 59 | 14 |
| Atenolol | Atenolol | 58 | 24 |
| Finasteride | Finasteride | 58 | 18 |
| Lorazepam | Lorazepam | 56 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 56 | 21 |
| Valsartan | Valsartan | 55 | 22 |
| Bupropion Xl | Bupropion Hcl | 54 | 16 |
| Enalapril Maleate | Enalapril Maleate | 54 | 19 |
| Fenofibrate | Fenofibrate,micronized | 52 | 30 |
| Nabumetone | Nabumetone | 52 | 25 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 52 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 51 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 49 | 23 |
| Pioglitazone Hcl | Pioglitazone Hcl | 49 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | 16 |
| Synthroid | Levothyroxine Sodium | 46 | 11 |
| Fluconazole | Fluconazole | 44 | 37 |
| Meclizine Hcl | Meclizine Hcl | 44 | 30 |
| Metformin Hcl Er | Metformin Hcl | 44 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 44 | 38 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | 16 |
| Pregabalin | Pregabalin | 43 | 13 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 42 | 18 |
| Diazepam | Diazepam | 42 | 14 |
| Ondansetron Odt | Ondansetron | 42 | 17 |
| Entresto | Sacubitril/Valsartan | 41 | 13 |
| Naproxen | Naproxen | 41 | 17 |
| Nifedipine Er | Nifedipine | 41 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 40 | 33 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 39 | 26 |
| Nitroglycerin | Nitroglycerin | 39 | 24 |
| Januvia | Sitagliptin Phosphate | 37 | 15 |
| Spironolactone | Spironolactone | 37 | 15 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 35 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | 13 |
| Fenofibrate | Fenofibrate | 35 | 13 |
| Linzess | Linaclotide | 35 | 12 |
| Estradiol | Estradiol | 33 | 14 |
| Cephalexin | Cephalexin | 32 | 26 |
| Levetiracetam | Levetiracetam | 32 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 32 | 17 |
| Donepezil Hcl | Donepezil Hcl | 31 | 12 |
| Glipizide Er | Glipizide | 31 | 12 |
| Benzonatate | Benzonatate | 30 | 28 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 30 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 30 | suppressed |
| Methotrexate | Methotrexate Sodium | 30 | suppressed |
| Mounjaro | Tirzepatide | 30 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 29 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 29 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 29 | 14 |
| Latanoprost | Latanoprost | 29 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 29 | suppressed |
| Topiramate | Topiramate | 28 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | 12 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Ciclopirox | Ciclopirox | 25 | 14 |
| Lactulose | Lactulose | 25 | 14 |
| Valacyclovir | Valacyclovir Hcl | 25 | 14 |
| Amiodarone Hcl | Amiodarone Hcl | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 21 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 23 | suppressed |
| Methocarbamol | Methocarbamol | 23 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 21 |
| Paxlovid | Nirmatrelvir/Ritonavir | 23 | 23 |
| Risperidone | Risperidone | 23 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 22 | suppressed |
| Irbesartan | Irbesartan | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | 12 |
| Levemir Flexpen | Insulin Detemir | 21 | 11 |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Potassium Chloride | Potassium Chloride | 21 | 13 |
| Trulicity | Dulaglutide | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Eszopiclone | Eszopiclone | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 19 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Indomethacin | Indomethacin | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | 17 |
| Repatha Syringe | Evolocumab | 17 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 17 | suppressed |
| Clotrimazole | Clotrimazole | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Carisoprodol | Carisoprodol | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 15 | 14 |
| Droplet Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Lumigan | Bimatoprost | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | 13 |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Codeine Sulfate | Codeine Sulfate | 12 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Wegovy | Semaglutide | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
| Minoxidil | Minoxidil | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,643.30 · 64 records | GlaxoSmithKline, LLC. | ACCRUFER, AREXVY, ELIQUIS, FARXIGA, General - Pain Management, JARDIANCE, Kerendia, Korlym, LUMRYZ, MOUNJARO, NURTEC ODT, OPSUMIT, OPSYNVI, OTEZLA, Ozempic, PAXLOVID, PRECIVITYAD2, REPATHA, SHINGRIX, TRELEGY ELLIPTA, UPTRAVI, VOQUEZNA, Wegovy, YUPELRI, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error